Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.

Trial Details

NCT ID
NCT06795009
Phase
PHASE1
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Zanzalintinib
  • Paclitaxel
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Albuquerque, New Mexico, United States|35.08449,-106.65114
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Diagnosis of recurrent, FIGO grade 3 endometrioid, serous, or mixed high grade uterine or endometrial cancer or uterine carcinosarcoma. Patients mu…
  • 1-2 prior lines of anti-cancer therapy are allowed.
  • Subjects who have received prior treatment with trastuzumab, pembrolizumab, or dostarlimab can enroll in the study. Use of these agents together or…
  • Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any pr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →